Clearside Biomedical, Inc. to Report Second Quarter 2016 Financial Results

ALPHARETTA, Ga., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, will provide a corporate update and report financial results for the second quarter ended June 30, 2016 before the NASDAQ market opens on Thursday, August 11, 2016.

The company will not be conducting a conference call in conjunction with this earnings release.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly-traded, late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye. Clearside has a portfolio of clinical and pre-clinical programs using drug administration through the suprachoroidal space to provide a route of access to treat diseases of the back-of-the-eye such as retinal vein occlusion (RVO), uveitis, neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Clearside is currently enrolling patients in a Phase 3 clinical trial (PEACHTREE) for the treatment of patients with macular edema associated with non-infectious uveitis and has initiated IND-enabling studies for the treatment of wet AMD. Visit www.clearsidebio.com for more information.


Contacts Company: Charles Deignan Chief Financial Officer 678-270-4005 charlie.deignan@clearsidebio.com Investors: Matthew Beck The Trout Group 646-378-2933 mbeck@troutgroup.com

Source:Clearside Biomedical, Inc.